Boston Scientific

SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX, EAR

Retrieved on: 
Tuesday, January 9, 2024
Advertising, Harpoon, Eargo, Fraud, Boston Scientific, Johnson & Johnson, Sale, Therapy, Security (finance)

If you are a Harpoon shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • If you are an Ambrx shareholder, click here to learn more about your rights and options .
  • If you are an Axonics shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on: 
Monday, January 8, 2024
ADS, Harpoon, Johnson & Johnson, Brodsky, AstraZeneca, J&J, Boston Scientific, JNJ, AZN, MRK, BSX, Security (finance)

BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, January 8, 2024
Legal, Professional Services, Advertising, Boston Scientific, Fraud, Sale

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per share is fair to Axonics shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per share is fair to Axonics shareholders.
  • On behalf of Axonics shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Technology, Total, Patient, Form 10-K, Boston Scientific, Incontinence, J. P. Morgan, BSX, Pharmaceutical industry

“Revenue grew 27% in 4Q23 and 34% in FY23, driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts.

Key Points: 
  • “Revenue grew 27% in 4Q23 and 34% in FY23, driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts.
  • In 2023, our team is humbled and gratified that clinicians used Axonics therapies to treat approximately 100,000 incontinence patients globally.”
    The preliminary revenue results below are unaudited and remain subject to adjustment.
  • Total company net revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022.
  • Sacral neuromodulation revenue is expected to be approximately $291.7 million, an increase of 31% compared to fiscal year 2022.

Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results

Retrieved on: 
Friday, January 5, 2024
Webcast, Boston Scientific, BSX, News

MARLBOROUGH, Mass., Jan. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday, January 31, 2024, at 8:00 a.m.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday, January 31, 2024, at 8:00 a.m.
  • The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer.
  • The company will issue a news release announcing financial results for the fourth quarter on January 31 prior to the conference call.
  • A live webcast and replay of the webcast will be accessible at https://investors.bostonscientific.com.

Moximed Announces Appointment of Dave Amerson to Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Medical Devices, Health, Surgery, Health Technology, Physical Therapy, General Health, FDA, Boston Scientific, Standard of care, OA, Amerson, Patient, Teleflex

Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Dave Amerson has joined the company’s Board of Directors.

Key Points: 
  • Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Dave Amerson has joined the company’s Board of Directors.
  • “Dave has established an unrivaled track record of successful commercialization of new medical device technologies,” said Anton Clifford, Ph.D., founder and CEO of Moximed.
  • We are excited to welcome him to our Board.”
    “I am thrilled to join Moximed’s Board of Directors at this exciting point in the company’s commercial trajectory,” said Mr. Amerson.
  • Amerson joins Josh Makower (Chairman), Anton Clifford, Arthur Franken, Shahzad Malik, Matt McAviney, Hank Plain, Kevin Sidow, Brigitte Smith, and David van Meter on Moximed’s Board of Directors.

Vensana Capital Strengthens Team with Promotions and Addition of Venture Partner

Retrieved on: 
Thursday, January 4, 2024
Other Professional Services, Finance, Health, Consulting, Health Technology, Professional Services, Technology, Other Technology, Yee, Navigant Consulting, Associate, Piper Sandler Companies, Coronary thrombosis, ATS Medical, Thoratec, Cardiology, EV3, Biotechnology, CFO, Partner, Acquisition, Boston Scientific, Medtech, NEA, Amrinder Singh, Therapy, MGM+, Medtronic, Engineering, Elective surgery, Investment, IPO, KPMG, Patient, CRG, Capital, Neurology, DSM-IV codes, Management

Vensana Capital , a leading medical technology-focused venture capital and growth equity investment firm, today announced the promotions of Amrinder Singh, Cynthia Yee, Greg Banker, and Mike Kramer to Partner and Steve Schwen to Partner & Chief Financial Officer.

Key Points: 
  • Vensana Capital , a leading medical technology-focused venture capital and growth equity investment firm, today announced the promotions of Amrinder Singh, Cynthia Yee, Greg Banker, and Mike Kramer to Partner and Steve Schwen to Partner & Chief Financial Officer.
  • The firm also announced the addition of veteran medtech leader Bill Hoffman as a Venture Partner.
  • “Since launching Vensana in 2019, we have set out to build the deepest, most experienced team in our sector.
  • Bill Hoffman joins Vensana Capital as a Venture Partner.

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

Retrieved on: 
Tuesday, November 21, 2023
Physician, Research, Robotics, FDA, CMO, Boston Scientific, NYU, Interventional oncology, Clinical trial, IDE, Investment, Patient

Dr. Diaz-Cartelle brings to Microbot a wealth of experience in the endovascular and interventional space, along with an impressive track record in clinical research.

Key Points: 
  • Dr. Diaz-Cartelle brings to Microbot a wealth of experience in the endovascular and interventional space, along with an impressive track record in clinical research.
  • In this role, he played a pivotal part in the development of global clinical strategy and study oversight, supporting commercial activities and future pipeline development.
  • "We are fortunate to have Dr. Diaz-Cartelle join our team, especially with his extensive experience in the endovascular and interventional space.
  • The Company is grateful for Dr. Morag's vast contribution to the Company over the years and wishes him success in his next ventures.

Neurology Devices Global Market Outlook to 2028, with Profiles of Medtronic, Abbott, Terumo, Boston Scientific Corp., Natus Medical and Siemens Healthineers - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Medical Devices, Health, Surgery, Neurology, Radiology, Biotechnology, Patient, Quality of life, Boston Scientific, Alzheimer's disease, DSM-IV codes, Research, Aneurysm, Stenosis, Epilepsy, Multiple sclerosis, Prevalence, Neurodegenerative disease, Stroke, Parkinson's disease, Medtronic, Siemens Healthineers, Growth, Investment, Row, Diagnosis, Medical imaging

Aging Population: The growing worldwide elderly population is a significant driver of the neurology devices market.

Key Points: 
  • Aging Population: The growing worldwide elderly population is a significant driver of the neurology devices market.
  • The rising prevalence of these conditions and the increasing number of patients resistant to medication drive the demand for neurology devices.
  • Based on product type, the market is segmented into neurosurgical devices, neuromodulation devices, neurovascular devices and neurodiagnostic devices.
  • This report examines the factors driving growth in the neurology devices market, and it reviews major players, established companies, and new entrants.

Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm

Retrieved on: 
Tuesday, December 19, 2023
Health care, PFA, Physician, FDA, Boston Scientific, Clarivate, Growth, IDE, COVID-19, Medtronic, Electrophysiology, CLVT, Patient, Organization, Intelligence, EP, Atrial fibrillation, Medtech, Tourism

LONDON, Dec. 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of a new special report series,  Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific. Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm.

Key Points: 
  • The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific.
  • Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm.
  • PFA has emerged as a breakthrough technology for the treatment of atrial fibrillation, attracting significant investment from several companies dedicated to its development.
  • Growth in market revenues will be driven by increasing ablation procedure volumes and the uptake of premium-priced devices.